These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33308268)

  • 1. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
    Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
    Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of Mcl-1 inhibitors for cancer therapy.
    Negi A; Murphy PV
    Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
    Yamaguchi R; Lartigue L; Perkins G
    Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
    Hird AW; Tron AE
    Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
    Li K
    Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents.
    Lu X; Liang H; Orvig C; Chen ZF
    Curr Mol Med; 2021; 21(5):426-439. PubMed ID: 32990536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
    Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
    Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.